Epcoritamab Shows Promise in Large B-Cell Lymphoma
Epcoritamab elicits durable responses in patients with relapsed or refractory large B-cell lymphoma.
Epcoritamab elicits durable responses in patients with relapsed or refractory large B-cell lymphoma.
Rapcabtagene autoleucel may elicit durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
Results of a phase 1/2 trial suggest the combination of atezolizumab and R-CHOP does not warrant further study in DLBCL, according to researchers.
Tisagenlecleucel plus pembrolizumab produced responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
The aim of this trial was to evaluate the efficacy and safety of orelabrutinib plus R-CHOP in patients with extranodal non-GCB DLBCL.
Severe persistent cytopenia was resolved in 5 of 6 patients.
Researchers sought to determine whether combination pola-R-CHP would be cost-effective for patients with previously untreated DLBCL.
Overall, there was no improvement in complete response or survival outcomes among patients who received bortezomib.
A large proportion of patients with relapsed/refractory diffuse large B-cell lymphoma do not undergo repeat biopsy, a study suggests.
A model including 4 clinical factors can predict overall survival, with predictive performance superior to the Ann Arbor staging system.